Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 (otesaconazole), in China, including mainland China, Hong Kong, Macau, and Taiwan, for the treatment or prevention of a range of fungal conditions, including recurrent vulvovaginal candidiasis (RVVC), onychomycosis and invasive fungal infections.
Pfizer has signed an agreement to acquire commercial stage biopharmaceutical firm, Array BioPharma, for an enterprise value of around $11.4bn (£9.06bn).
IBM, KPMG, Merck and Walmart announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the US Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the US.
Ligand Pharmaceuticals and PhoreMost have announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.
Dassault Systèmes has signed an agreement to acquire US-based Medidata Solutions for an enterprise value of $5.8bn (£4.5bn).
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins.
AptarGroup has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical, for a combined enterprise value of approximately $50m (£39.3m).
Merck has signed an agreement to acquire biopharmaceutical firm Tilos Therapeutics in a deal valued at around $773m (£608m).
nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.
Vertex Pharmaceuticals has signed an agreement to acquire US-based Exonics Therapeutics in a deal valued up to $1bn (£787m).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.